Results per Page:
Improving blood stem cell transplantation outcomes by treating donors
From the Mielcarek Group, Clinical Research Division
Fred Hutch blood and marrow transplant program recognized nationally for patient survival outcomes
Industry data report shows Fred Hutch among 6.3% of U.S. transplant centers to exceed outcomes expectations
Bone marrow transplant survival rates recognized nationally
Fred Hutch BMT program at SCCA earns national recognition for 6th consecutive year
3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant
$20M renewal of 4-decade-long federal grant to Hutch scientists
Fred Hutch/SCCA transplant patient survival above the expected rate in U.S.
For 5th year in a row, bone marrow transplant program receives top recognition
Fred Hutch/SCCA transplant rates among best in U.S.
Fred Hutch Bone Marrow Transplant Program recognized for outperforming expected one-year survival rates for allogeneic transplant patients
Fred Hutch/SCCA transplant rates among best in U.S.
Nobel Prize-winning transplant program receives top recognition four years in a row.
Mielcarek study may change the practice of blood stem-cell transplantation
Celebrating faculty and staff achievements
Life with graft-vs.-host disease: When the transplant is just the beginning
How researchers are trying to combat this common, often debilitating side effect of treatment
Gentler treatment for many with graft-vs.-host disease
A new study finds halving standard steroid dose treats most acute GVHD just as well; could limit dangerous side effects
Mielcarek lands $2.2 million GVHD grant
NHLBI grant will expand research into protective mechanisms of statins against severe acute graft-vs.-host disease in transplant patients